Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2021

View Archived Issues

Keymed evaluates CM-310 in phase II for chronic rhinosinusitis with nasal polyposis

PEP-010 enters first-in-human study in solid tumors

iBio advances COVID-19 vaccine programs

Russia authorizes use of single-dose Sputnik Light COVID-19 vaccine

Sangamo Therapeutics patents chimeric antigen receptors targeting IL-23

Lead Pharma Holding presents new ERR-alpha inverse agonists

New TRPA1 antagonists identified at Boehringer Ingelheim

PTPN11 inhibitors discovered at Hangzhou Rex Pharmaceutical

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

UCB identifies antiepileptic compounds improving on padsevonil

Study of a new CAIX-targeting radiotracer, [99mTc]PHC-102, for SPECT imaging in ccRCC patients

SparingVision studies ocular gene therapy SPVN-06 in primates

GQ-127 shows in vitro and in vivo antitumor activity in uveal melanoma

Reduced galectin-3 observed in central serous chorioretinopathy

Allysta Pharmaceutical initiates first-in-human study of ALY-688-SR

Enrollment ongoing in phase II study of JNJ-40411813 as adjunctive therapy in epilepsy

NuBiyota starts phase II study of MET-2 in subjects with major depression

Enrollment begins in phase II study of NeoVax cancer vaccine in patients with CLL

Telix cleared in Australia to begin phase III study of TLX-591 for metastatic CRPC

KNP-301 tested in mouse models of AMD

VIP-236 demonstrates potent antitumor efficacy in xenograft models

China NMPA approves bevacizumab biosimiilar LY-01008

Preclinical data presented for the ocular anesthetic AG-920

Cantargia plans to study CAN-04 with carboplatin/gemcitabine in advanced TNBC

Phase III FIGARO-DKD cardiovascular outcomes study of finerenone meets primary endpoint

Findings bolster RAD51 as biomarker for DNA repair deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...